A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who are Resistant to or Intolerant of Hydroxyurea
Study of Experimental Drug in Patients with Elevated Thrombocythemia (Too Many Platelets, Leading to Abnormal Blood Clotting or Bleeding)
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAR3247
U.S. Govt. ID: NCT03123588
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the safety, tolerability, and effectiveness of ruxolitinib, an investigational drug, compared to anagrelide, an FDA approved drug. Investigational means that the study drug has not been approved by the FDA for treatment of ET. Patients will be assigned to one of two groups. Group A will receive ruxolitinib and placebo; Group B will receive anagrelide and placebo.
This study is closed
Mark Heaney, MD, PhD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with elevated thrombocythemia (too many platelets, leading to abnormal blood clotting or bleeding)? Yes No
Are you able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator